Literature DB >> 19732690

Inflammatory breast cancer.

Wendy A Woodward1, Massimo Cristofanilli.   

Abstract

Inflammatory breast cancer (IBC) represents the most virulent form of breast cancer, characterized by involvement of the skin and rapid progression of the disease. Management involves careful coordination of all multidisciplinary modalities, including imaging, systemic chemotherapy, surgery, and radiation therapy. The use of neoadjuvant chemotherapy has contributed significantly to improvement in overall survival since the first descriptions of this entity and has made the role of locoregional therapy, including surgery and radiation critical to continued improvements in this disease. In this article, we examine the unique epidemiology and pathology of IBC and review the various treatment modalities noting the significance of a multimodality approach and delineating each of the specific components. Moreover, we briefly describe the current research in IBC that will hopefully contribute further to improve systemic therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19732690     DOI: 10.1016/j.semradonc.2009.05.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  21 in total

1.  The need for post-mastectomy radiotherapy in patients with IBC.

Authors:  Gustavo Ruiz Ares; Eva Ciruelos; Luis Manso
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

2.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

3.  Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate.

Authors:  Xiaodong Ye; Diane Fels; Artak Tovmasyan; Katherine M Aird; Casey Dedeugd; Jennifer L Allensworth; Ivan Kos; Won Park; Ivan Spasojevic; Gayathri R Devi; Mark W Dewhirst; Kam W Leong; Ines Batinic-Haberle
Journal:  Free Radic Res       Date:  2011-09-27

4.  Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration.

Authors:  C L Buchheit; B L Angarola; A Steiner; K J Weigel; Z T Schafer
Journal:  Cell Death Differ       Date:  2014-12-19       Impact factor: 15.828

5.  ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.

Authors:  Katherine M Aird; Jennifer L Allensworth; Ines Batinic-Haberle; H Kim Lyerly; Mark W Dewhirst; Gayathri R Devi
Journal:  Breast Cancer Res Treat       Date:  2011-05-11       Impact factor: 4.872

6.  Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.

Authors:  Balraj Singh; Kendra R Cook; Cecilia Martin; Eugene H Huang; Kailash Mosalpuria; Savitri Krishnamurthy; Massimo Cristofanilli; Anthony Lucci
Journal:  Clin Exp Metastasis       Date:  2010-03-13       Impact factor: 5.150

7.  Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Authors:  Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi
Journal:  Cancer Lett       Date:  2013-05-17       Impact factor: 8.679

8.  Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.

Authors:  Rahul Ravind; Priyadarshini Venkatram Kumar; Sasikala Prabaharan
Journal:  BMJ Case Rep       Date:  2016-04-08

9.  RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.

Authors:  Michelle L Wynn; Joel A Yates; Charles R Evans; Lauren D Van Wassenhove; Zhi Fen Wu; Sydney Bridges; Liwei Bao; Chelsea Fournier; Sepideh Ashrafzadeh; Matthew J Merrins; Leslie S Satin; Santiago Schnell; Charles F Burant; Sofia D Merajver
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

10.  Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.

Authors:  Naveen Chintalaramulu; Raja Vadivelu; Nam-Trung Nguyen; Ian Edwin Cock
Journal:  Inflammopharmacology       Date:  2020-05-06       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.